Medicago awarded funding from Quebec's Consortium for Drug Discovery.(NEWS

Medicago Inc., a biotechnology company specializing in developing vaccines based on proprietary manufacturing technologies, announces that it has been awarded $11.77 million in funding by Quebec's Consortium for Drug Discovery (CQDM).

"We are pleased to have been selected by CQDM for this funding which launches the next phase in the development of our virus-like particles (VLPs) vaccine technology and will ultimately allow us to expand our product pipeline," says Andy Sheldon, president and CEO of Medicago.

"VLPs represent one of the most promising approaches for the production of vaccines. There is a need for new cost-effective technological solutions to speed-up and streamline the development of CLP vaccines from early research to clinical testing."

Medicago will use the funding to develop VLPExpress, a high throughput platform that will accelerate the company's discovery and development of new vaccines by rapidly expressing, purifying and testing candidate VLPs.

Medicago's VLPExpress platform will identify the best VLP-based antigen presentation for a disease-causing agent within 10 weeks. Each antigen will be screened for their potential to provide protection.

Medicago Inc.

Print Get the Mag Weekly Updates